HOBOKEN, N.J. (PRWEB)
January 07, 2020

Vuja De Sciences (“Vuja De”), a biotechnology startup dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence, today announced the appointments of Chand Khanna, DVM, PhD, DACVIM (Onc), and Dr. Lee Helman, MD, to its Board of Directors. Rick Lampe, Co-founder and CEO of Vuja De said, “We are delighted to welcome Chand and Lee as new directors. They will be of great help in advancing our unique approach to the discovery and development of metastatic progression targeting cancer treatments in osteosarcoma and other cancers.” Dr. David Warshawsky, Vuja De’s Founder and Chairman of the Board added: “I am confident that their leadership will have a highly meaningful impact on Vuja De’s ability to translate our core anti-metastasis drug discovery platform to ground-breaking therapies against cancer progression and to our success in building a strong and leading company in the fight against cancer.”

Vuja De has been collaborating with Dr. Chand Khanna, Chief Science Officer of Ethos Veterinary Health and President of Ethos Discovery. Through this interaction VuJa De and Ethos have an innovative collaborative plan and path for metastasis-focused drug development that includes clinical trials in pet dogs with cancer (i.e. comparative oncology). “I am delighted to join the leadership at Vuja De. Targeting metastatic progression has been my passion for over 20 years and the team at Vuja De stands poised to rapidly translate new findings from its metastasis drug screens to effective drugs for the primary unmet need for cancer patients,” said Dr. Khanna.

Dr. Lee Helman stated: “I am delighted to join the Vuja De board and to work with the team to do whatever is needed to help bring treatments that prevent cancer progression and recurrence to patients with osteosarcoma and other cancers.”

“Ethos Veterinary Health is excited and highly supportive of the planned collaboration with Vuja De, beginning with Dr. Khanna joining the leadership team and soon leading to comparative oncology clinical trials that will develop effective treatments for both human and canine cancer patients,” said Ames Prentiss, CEO of Ethos Veterinary Health.

Dr. Chand Khanna

Dr. Khanna was the longtime Head of the NCI Pediatric Oncology Branch’s Tumor and Metastasis Biology Section, and the Founding Director of the Center for Cancer Research, Comparative Oncology Program. His research interests and responsibilities focused on the problem of cancer metastasis and the discovery of new options to treat patients with metastasis. Dr. Khanna has over 100 publications in the area of cancer biology and therapy. He is currently the Chief Science Officer of Ethos Veterinary Health and President of the non-profit incubator of scientific innovation, Ethos Discovery (501c.3.). In these roles Dr. Khanna seeks to improve outcomes for human and pet patients with complex medical problems through the development of novel therapeutics and diagnostics.

Dr. Lee Helman

Dr. Helman is Section Head of Basic and Translational Research within the Children’s Center for Cancer and Blood Diseases and Director of the Cancer and Blood Diseases Research Program of the Saban Research Institute of Children’s Hospital Los Angeles. He is also Professor of Pediatrics in the Keck School of Medicine of USC. Dr. Helman has been studying the biology and caring for pediatric patients with sarcomas for over thirty years. He has also trained many investigators in the field of pediatric sarcomas. One current area of active research at Children’s Hospital Los Angeles focuses on using full genomic classification of osteosarcoma tumors to improve therapy, as well as testing novel therapeutic drugs and drug combinations in patients with osteosarcoma. Dr. Helman received his medical degree from the University of Maryland School of Medicine magna cum laude in 1980 and was elected to Alpha Omega Alpha. He has served as scientific director for clinical research in the Center for Cancer Research at the NIH until 2016. He was elected to the American Society for Clinical Investigation and the American Association of Physicians and is a founding member and past president of the Connective Tissue Oncology Society. He is a past member of the Board of Governors of the Clinical Center at NIH. In addition to his many appointments with different organization, he has been appointed director of the Osteosarcoma Institute.

About Comparative Oncology

In the setting of cancer drug development, comparative oncology involves the inclusion of dogs with naturally occurring cancer in clinical trials, where novel or repurposed drugs are tested to answer questions that cannot be answered in conventional animal models of cancer or human clinical trials.

About Osteosarcoma

Osteosarcoma is an aggressive cancer of the bone in dogs and human patients and is the most common type of bone cancer in children and teens. Despite successful control of the primary tumor and follow-up chemotherapy, metastasis continues to be the most common cause of mortality for both species. The last 30 years have brought little improvement in survival outcomes for children with osteosarcoma, despite intensification of therapy. Due to lack of improved outcomes, new approaches to therapy are highly needed. Furthermore, if targeted therapeutics are found to prevent metastasis in this human cancer, a strong biological rationale would exist for the evaluation of such a therapy in other human cancers.

About Ethos Veterinary Health

Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning, growth for team members, and the development of collaborative relationships. For more information, visit ethosvet.com.

About Ethos Discovery

Ethos Discovery is a 501(c)3 non-profit incubator of scientific innovation that seeks to improve health outcomes in pets and humans with complex medical problems, including cancer. For more information, please visit ethosdiscovery.org

About Vuja De Sciences

Vuja De is a biotechnology startup dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence. Our initial focus is osteosarcoma. We utilize leading laboratory technologies for metastatic preclinical endpoints in combination with Comparative Oncology to de risk and inform product development and maximize likelihood for successful human oncology clinical trials. We are testing repurposed drugs that have previously been in human clinical trials, as well as novel preclinical drugs. For more information, please visit vujade-life.com.

Share article on social media or email:

HERNDON, Va. (PRWEB)
January 07, 2020

Liberty IT Solutions LLC, which specializes in Health Information Technology, has been awarded a four-year (12-month Base Period plus three 12-month Option Periods) Task Order (TO) to enhance operability of the System Center Configuration Manager (SCCM) for the Department of Veterans Affairs (VA).

SCCM is the VA’s central patching tool for all updates to endpoints enterprise-wide. Continued SCCM system health is vital to VA’s ability to deliver up-to-date services across the country. Under this TO, Liberty, along with its partner ManTech International Corporation, will support the SCCM hardware/software and updates needed to maintain this system health. This also includes support for VA field offices to enable staff to efficiently troubleshoot problems and conduct maintenance activities.

Liberty CEO, Bill Greene, says of the win: “Enhancing the operability of the System Center Configuration Manager is an important task that Liberty is looking forward to working on with VA. We are excited to continue to modernize SCCM, in keeping with our commitment to the future of Health IT and a higher standard of service for Veterans.”

As the number of endpoints continues to rapidly expand and diversify, Liberty will also work to modernize the system, incorporating innovative technologies and project management approaches that will enhance cloud and mobile capabilities on SCCM. These efforts will ensure that SCCM can continue to support care for Veterans now and as their needs develop into the future.

About Liberty

Liberty IT Solutions delivers transformative services and support to multiple government agencies across a diverse portfolio of Health IT projects. Our team believes that lines of code can change lives and is driven to enable that to happen more often, more securely and more efficiently.

If you would like more information about this topic, please contact Liberty IT Solutions at 571.356.9627 or email at transformation@libertyits.com.

Share article on social media or email:

SAN FRANCISCO (PRWEB)
January 07, 2020

With the close of the open enrollment period in the 38 states using the federal health insurance Marketplace, HealthSherpa announced its 2020 open enrollment results.

Between November 1st and December 17th, 2019, HealthSherpa enrolled 1.2 Million people in ACA coverage – a 143% increase over the prior Open Enrollment period. Over 31,000 of these enrollees were able to take advantage of the deadline extension granted by the Centers for Medicare and Medicaid Services. In total, HealthSherpa accounted for over 14% of ACA enrollments across the 38 Federal Marketplace states.

Most HealthSherpa consumers found coverage for $47/month or less, and 72% enrolled in silver plans, which offer comparable coverage to employer-sponsored health insurance. In aggregate, HealthSherpa has enrolled over 3 million Americans in on-exchange health insurance since 2014.

HealthSherpa is one of a handful of companies approved to use the Department of Health and Human Services’ innovative new Enhanced Direct Enrollment (EDE) technology, and was the first company granted approval on November 28th, 2018. In the 2020 Open Enrollment Period, HealthSherpa hosted the EDE platform for 37,000 insurance agents and over 15 insurance carriers.

EDE permits private companies to carry out all enrollment and related activities for on-exchange health coverage. HealthSherpa is approved for Phase 3, which allows HealthSherpa to process all applications, including those for rare tax circumstances, end-to-end on HealthSherpa.com.

“Continued strong enrollment year over year shows that consumers and issuers alike are deeply invested in the ACA Marketplace,” said HealthSherpa CEO George Kalogeropoulos. “Technologies like Enhanced Direct Enrollment are making it easier than ever for issuers, agents, employers, and other stakeholders to help Americans enroll in comprehensive coverage, and to help them manage that coverage throughout the year. We are proud to be at the forefront of ACA enrollment and to have the privilege of helping millions of Americans access the peace of mind that can only come with high-quality, ACA-compliant coverage.”

About HealthSherpa

HealthSherpa partners with large employers, insurers, as well as insurance agencies and agents to support consumers searching for, enrolling in and utilizing high quality, affordable health insurance coverage. HealthSherpa only sells ACA marketplace plans, which have built-in consumer protections, and since its founding in 2014, has enrolled over 3 million Americans in Affordable Care Act coverage. For more information, visit http://www.healthsherpa.com.

Share article on social media or email:

SALT LAKE CITY and LAS VEGAS (PRWEB)
January 06, 2020

After 32 years in Stealth Mode, LumaCare™ emerged today to announce its formation and unveil its first product: The LumaCare Duo™.

The first public demonstrations of the LumaCare Duo will be given in the LumaCare booth (#44868) in the Sands Convention Center in Las Vegas, Nevada during CES 2020, the largest consumer electronics trade show and conference in the United States. Additionally, LumaCare will preview the LumaCare Duo from 7—10:30pm tonight to credentialed journalists, analysts, and influencers during the PEPCOM Digital Experience! press event at the Mirage Hotel Events Center on the Las Vegas Strip.

The LumaCare Duo is a handheld, wireless, and rechargeable “Cold Laser” device that features two rotating emitter heads, one each at opposite ends of jointed arms, to offer nearly 180 degrees of motion for delivering three different pulsating spectrums of therapeutic light to injured body parts. Each emitter head has a peak combined power output of 60 Watts from the 15 laser diodes and LEDs, specifically:

• 
  Four Infrared laser diodes at 905nm (nanometer wavelengths),
• Six Infrared laser diodes at 808nm, and
• Five visible Red LEDs at 670nm, for a total of 30 laser diodes/LEDs per LumaCare Duo system.

Because the patent pending LumaCare Duo features two articulating emitter heads affixed to the ends of two movable arms, users can manipulate the device to direct therapeutic laser light at injured tissue from two directions at the same time. Additionally, having two emitter heads also allows LumaCare Duo users to focus more Infrared and visible Red light over a wider area if needed. Users may also choose to implement only one emitter head if that is what the treatment protocol requires.

BACKGROUND INFO ON LUMACARE AND “COLD LASER” THERAPIES

LumaCare is the brainchild of National Laser Company, a 32-year-old company focused on the industrial, commercial and medical laser marketplace, a firm that has primarily worked behind the scenes as a private label and/or original equipment manufacturer (OEM) and service provider to other laser companies.

Given this foundation of over 30 years of laser industry experience and expertise, the executive team at LumaCare is very familiar with the role of Cold Lasers / Low-Level Laser Therapy (LLLT) as a treatment protocol for a wide variety of chronic and traumatic injuries.

“The reality is that over the past five decades thousands of peer-reviewed articles, studies and reports have been published about the efficacy of Cold Lasers as part of certain treatment regimens,” said Kevin Waller, COO and co-founder of LumaCare. “In fact, the very first inkling of the potential therapeutic benefits of LLLT came in 1967 when Endre Mester discovered that treatments of Cold Laser light regrew hair on mice.

“Studies in the ensuing 50-plus years have shown particular benefit from three wavelength bandwidths: from 650—675nm for surface/skin-level treatments, from 800—825nm for medium depth treatments, and from 900—925nm for deeper tissue/joint treatments. Since Dr. Mester’s finding, hundreds of thousands of Cold Laser systems have been used to improve blood flow, boost oxygenation, reduce inflammation and pain, and enhance cellular recovery for traumatic and chronic injuries.”

MORE LUMACARE DUO DETAILS, PRICING AND AVAILABILITY

The LumaCare Duo weighs 10.75 ounces, measures 4.75- x 5.63- x 2.75-inches (height x width x depth) when folded/closed and 3.25- x 11.50- x 2.75-in. when fully open, while the emitter heads measure 2.1- x 2.7- x 0.6-in. The range of motion of the LumaCare Duo is ~90 degrees per arm and ~135° per emitter head, with a total range of motion of ~180° when the device is fully open.

The LumaCare Duo is classified by the U.S. Food and Drug Administration as a Class 1 laser and is expected to have a suggested retail price of under $3,000.00 (US). However, the LumaCare Duo is currently in the latter stages of review by the FDA, with 510K Clearance anticipated by LumaCare in early 2020.

As a result, the LumaCare Duo is not available for purchase or resale at this time.

Nevertheless, fully functioning LumaCare Duo units are available now for evaluation purposes by healthcare professionals, credentialed journalists, and other qualified individuals and organizations.

For more information, please contact LumaCare at 801-924-8791 or via email at info@LumaCareLasers.com.

Relevant Hashtags: #LumaCare #LumaCareDuo #ces #CES2020 #medtech #healthtech #ColdLasers #CoolLaser #laser #lasertech #healthcare #medical #medicine #treatment

LumaCare and LumaCareDuo are trademarks of LumaCare.

CONTACT:

David Politis, LumaCare’s VP of Marketing & Sales, 801-556-8184 (cell), dpolitis@LumaCareLasers.com

Share article on social media or email:

FAIRFIELD, N.J. (PRWEB)
January 06, 2020

Medphine, a leading provider of US healthcare revenue cycle management services, is excited to welcome the new decade with great zeal, and with a promise to help more and more providers in experiencing freedom from financial burden. Medphine is offering a flat 20% discount to its first-time service users, enrolling in January 2020.

Medphine has provided full-stack revenue cycle management, billing and coding services from last one decade. The services be it front desk support or specialty-specific billing, are all aligned with the continually evolving healthcare landscape and ever-advancing technologies. It has enhanced it portfolio furthermore by taking an extra leap in helping healthcare organizations capture extra income through Chronic Care Management Assistance program, Patient Recall Services, and much more.

When asked about what makes clients trust Medphine as their service partner, Reetu Singh, CEO of Medphine said, “Medphine goes beyond the realm of a traditional medical billing company and has developed a culture which promotes excellence in work, our team is hardworking which reflects in our deliverables. We have successfully recovered practices from the verge of bankruptcy by deploying our team that takes untiring measures to recover their billable and today they credit Medphine for enabling them to multiply their practice and start new locations. We are expanding our portfolio and are acquiring new skills to be able to help more and more organizations in anything related to Healthcare.”

Today billing companies like to work on their proprietary billing platforms which blindsides the provider and their staff as they are not able to see the real action on patient’s claims and have to rely on monthly reports which further complicates and doesn’t always depict the clear picture of the practices actual financial health.

Medphine think from provider’s perspective thus we purposefully work on almost all major billing platforms such as eClinicalworks, Epic, Kareo, Athenahealth, Chirofusion, AdvancedMD, GE Centricity, etc. We enjoy sharing our learning with our clients which fulfills our objective to ensure transparency, visibility, and improvement in the financial performance of healthcare facilities. This is why we want more of our prospective clients to benefit from our services, said Reetu.

Medphine invests its time and resources to learn the billing environment and understand the uniqueness of each client. That is what makes Medphine stand out as a pioneer service provider who specialize in crafting customized solution to each of its clients.

Healthcare facilities that are looking for an expert RCM service provider to make the switch, or to take control of their finances, can now benefit from Medphine’s holistic approach which is now at a 20% discount rate for clients enrolling in January 2020.

About Reetu Singh:

Reetu started her journey in the healthcare industry as a medical biller using eClinicalworks and has efficiently learned all the intricacies of the medical billing process. She aims at bringing disruption in the healthcare industry with transparency. With over a decade of experience in US Healthcare RCM and billing landscape, Reetu taking Medphine forwards plans to fight and provide simple solutions to various challenges the healthcare industry is facing right now, such as Surprise medical bills, lack of mobility of records and high cost to patients. Reetu’s passion for continuously delivering better output has made Medphine stand proud in the list of top 10 RCM companies, earning the label of one of the most promising and trustworthy companies to work with.

About Medphine.com :

Medphine is a provider of exhaustive billing, coding, and revenue cycle management services to healthcare organizations in the United States. With the aim to streamline the RCM, maximize revenue, and reduce the overhead cost, they employ certified and experienced billers and coders and deploy the latest in technology.

From front desk support, appointment reminder through specialty-specific billing, and coding to transcription services for medical practices and pharmacies, Medphine’s holistic services guarantee minimum probability of claim denial and maximum profitability. Medphine has a long proven record of dispensing dedicated RCM services for ensuring a higher return on investment.

Contact:

Medphine.com

124 Little Falls Rd #205

Fairfield, NJ 07004

USA

Phone: 732-419-2907

Website: https://www.medphine.com/

Share article on social media or email: